Early Quality of Life Changes Predict Aromatase Inhibitor Therapy Discontinuation

Early changes in patient-reported outcomes during aromatase inhibitor (AI) therapy were associated with treatment discontinuation.
Early changes in patient-reported outcomes during aromatase inhibitor (AI) therapy were associated with treatment discontinuation.

Early changes in patient-reported outcomes during aromatase inhibitor (AI) therapy were associated with treatment discontinuation, a study published in the journal The Oncologist has shown.1

Although early discontinuation of aromatase inhibitors in common and leads to poor outcomes, it can be challenging to predict which patients with discontinue treatment. Therefore, researchers sought to determine whether early changes in patient-reported outcomes predict aromatase inhibitor discontinuation.

For the study, researchers analyzed data from 490 postmenopausal women with early stage breast cancer who were participants of a prospective randomized trial evaluating exemestane vs letrozole. Patients had completed questionnaires at baseline and over 24 months for researchers to assess overall quality of life, mood, and multiple symptoms, including musculoskeletal symptoms.

Results showed that worsening of quality of life (HR, 2.77; 95% CI: 2.72-2.81; P = .015) and musculoskeletal symptoms (HR, 4.39; 95% CI: 2.40-8.02; P < .0001) were associated with the highest risk for early treatment discontinuation.

However, researchers found no consistent association between pharmacokinetics of the aromatase inhibitors or estrogen metabolism and early changes in patient-reported outcome measures.

The findings ultimately suggest that identifying these changes could be used to design interventions to improve tolerance before significant toxicities develop in patients at high risk for early discontinuation.

The authors note that further research is necessary to improve the measurement of patient-reported outcomes in routine clinical practice.

REFERENCE

1. Kadakia KC, Snyder CF, Kidwell KM, et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer [published online ahead of print March 23, 2016]. Oncologist. doi:10.1634/theoncologist.2015-0349.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs